Yüksel Ürün

Every patient teaches me something new about strength, hope, and why we fight.

Yüksel Ürün: Science Is Better When It’s Shared - OncoDaily Yüksel Ürün: Science Is Better When It’s Shared / cancer, Headlines, OncoDaily, Oncology, Yüksel Ürün

Science Is Better When It’s Shared - Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/blog/science...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Science

Yüksel Ürün: Breast Cancer Care Shouldn’t Be a Luxury - OncoDaily Yüksel Ürün: Breast Cancer Care Shouldn’t Be a Luxury / Amal Arahmani, Ander Urruticoechea, Ankara University School of Medicine, Barbro Lindholm, Boon H.

Breast Cancer Care Shouldn’t Be a Luxury - Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/insight/yuks...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer

This sounds like an exciting step forward! How soon do you think cancer vaccines like these could become more widely used?

Yüksel Ürün: A Promising Option for Non–Clear-Cell Renal Cell Carcinoma - OncoDaily Yüksel Ürün: A Promising Option for Non–Clear-Cell Renal Cell Carcinoma / cancer, Craig Gedye, Cristina Suárez, David Pook, Erhan Gokmen, european urology,

A Promising Option for Non–Non-Clear-Cell Renal Cell Carcinoma - Yüksel Ürün
@yukselurun.bsky.social
@euplatinum.bsky.social

oncodaily.com/science/yuks...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #nccRCC #KidneyCancer

Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency? - OncoDaily Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency? / Ankara University School of Medicine, cancer, HRR Deficiency, mCRPC, metastatic

How Should We Treat mCRPC and HRR Deficiency? - Yüksel Ürün

@yukselurun.bsky.social

oncodaily.com/blog/how-sho...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #mCRPC #HRR #ProstateCancer

Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC - OncoDaily Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC / ADCs, Biokin Pharma, BMS, cancer, Minhua Chu, OncoDaily, Oncology, Paolo Tarantino,

First Positive Phase 3 Trial for a Bispecific ADC - Paolo Tarantino
@ptarantinomd.bsky.social
@yukselurun.bsky.social

oncodaily.com/insight/paol...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC

Cancer vaccines: the next frontier is now.
From HBV & HPV to personalized mRNA shots
@oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social

Take care of your kidneys, protect your life.
4 simple actions = less risk, better outcomes:
🚭 Quit smoking
⚖️ Stay at a healthy weight
🏃‍♀️ Be active, avoid trauma
💧 Drink water, skip alcohol
Because prevention is power
@oncoalert.bsky.social
@drchoueiri.bsky.social @kidneycan.bsky.social

🎗 Gerçek bilim bazen zor konuşur.
Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız.

📌 Evet, süreç yorucu.
📌 Evet, sonuç her zaman adil değil.
Ama geçmişe göre çok daha iyiyiz.
Birçok tümörde, yıllar kazandıran tedaviler var artık

Bugünkü kelimemiz: Radikal Prostatektomi

🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek?

👨‍⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır.
🎯 Bilmek güç verir.
Takipte kalın, diğer terimleri de birlikte öğrenelim.

🔬 Klinik Araştırma Nedir?
Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır.

Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar,
hem de gelecekte binlerce hayatın değişmesine katkı sağlar.
#science

Biyopsi = Şüpheli dokudan parça alıp mikroskopla incelemek.
Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.”

🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | NEJM Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...

I have two favourite studies from #ASCO25 @christielibrary.bsky.social @mcrcnews.bsky.social 👇🏽
www.nejm.org/doi/full/10....

Hypertension, Diabetes, and High Cholesterol Awareness Among US Adults This cross-sectional study evaluated the changes in the proportion of US adults who were unaware they had hypertension, diabetes, or a high cholesterol level using 2013 to 2023 data from the National ...

Our new JAMA Cardiology study finds that many US adults don't know that they have hypertension, diabetes, or high cholesterol

Nearly 1 in 3 young adults w/ hypertension, 2 in 5 with diabetes, and 1 in 4 with high cholesterol are unaware of their condition.

bit.ly/45an6MC #medsky #cardiosky

#ASMS2025 ThP046 come to check out Jenny’s poster! Don’t miss this great opportunity to meet Jenny! @asms.org @jyates.bsky.social @femalesinms.bsky.social #teammassspec @garcialabms.bsky.social @proteomicsnews.bsky.social

This is so true. We have to continually work together to get better #healthcare delivery & #research advances to ALL #patients.

Every oncologist is a patient advocate.
Right treatment.
Right time.
For every patient.
#ASCO25 #Oncology #CancerCare #AccessMatters
@oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social

Congrats dear Dr. Dizon 👏👏👏

Thrilled to share our new analysis from CheckMate 901!
🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS.
➡️A new horizon for a distinct subgroup.
@uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social

📢 Just in: Multivitamins after MI in diabetes?
🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes.
🎯 35% event rate in both arms HR: 0.99
No benefit.
#Cardiology #Diabetes #RCT #JAMA

Yüksel Ürün: Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - OncoDaily Yüksel Ürün: Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve / Amado J Zurita, Ana M. Aparicio, Ankara University School of Medicine, cancer,

Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/science/yuks...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer

New era for HER2-mutant lung cancer!
Zongertinib delivered a 71% response rate, 12.4 months median PFS!
No ILD reported.
Precision hitting its mark!
#LungCancer #Oncology #Targeted #cancerresearch
@nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social

Abstracts are out for #ASCO25!
5000+ studies. 5 Plenary game-changers.
@ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

The ESMO Research Fellowship is now open.
A chance to dive deep into science, grow globally, and shape the future of cancer care.
Ready to make impact?
@myesmo.bsky.social
@oncoalert.bsky.social
@ptarantinomd.bsky.social @antoniopassaro.bsky.social @drchoueiri.bsky.social

Many kudos to @ascocancer.bsky.social amazing #SoMe staff for putting together this great highlight of #ASCO25 planning.

Getting a moment to hang with the real stars 🤩 inc @ryannipp.bsky.social and my #MedEd colleagues. Looking forward to May in Chicago 🌃

Thrilled to announce that our article has been selected as a Top Viewed Article in Cancer journal!
“Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents”
Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social

Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊

What if we screened smarter, not just more?
In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy—
40% had prostate cancer.
Over half needed treatment.
Most would’ve been missed by PSA alone.
Genetics is rewriting the rules.
@nejm.org @myesmo.bsky.social @oncoalert.bsky.social

🧬 Genomic testing in childhood & young adult cancers:
🧬16–18% carry germline variants
🧬Somatic findings guide Dx in up to 95%
🧬Matched therapy? Often possible—rarely given
The science is ready. Let’s make care catch up.
@oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social